secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001641172-25-008956
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir-1 reverses cellular decline markers in human cell lines; supports autism and spasmodic dysphonia programs
--------------------------------------------------------------------------------

- New preclinical data show Telomir-1 improved cell viability under stress and boosted mitochondrial function in human cell lines.
- Telomir-1 reduced reactive oxygen species (ROS) and restored calcium signaling, limiting oxidative damage and maintaining cellular communication.
- Telomir-1 protected cells from iron- and copper-induced toxicity, which are linked to ROS formation and accelerated aging.
- Findings provide mechanistic foundation for new research initiatives in autism spectrum disorder (ASD) and spasmodic dysphonia (SD).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225008956/0001641172-25-008956-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225008956/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-008956

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer